✦ LIBER ✦

A phase II study ofcis-diamminedichloroplatinum II for advanced breast cancer two dose schedules

✍ Scribed by Silvana Martino; Bohumil A. Samal; Amnuay Singhakowinta; San Yoshida; Michael Mackenzie; Jitender Jain; Vainutis K. Vaitkevicius

Book ID: 112293835
Publisher: Springer-Verlag
Year: 1984
Tongue: English
Weight: 294 KB
Volume: 108
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf00390472

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Phase II study of divided-dose vinblasti

Phase II study of divided-dose vinblastine in advanced breast cancer patients

✍ Giuseppe Giaccone; Matteo Bagatella; Oscar Bertetto; Michela Donadio; Alessandro 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 231 KB

A phase II study of peptichemio in advan

A phase II study of peptichemio in advanced breast cancer

✍ V. Hug; G. N. Hortobagyi; A. U. Buzdar; G. R. Blumenschein; W. Grose; M. A. Burg 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 3 views

Phase II study of TCNU in advanced breas

Phase II study of TCNU in advanced breast cancer

✍ Dombernowsky, P.; Clavel, M.; Smyth, J.F.; Howell, A.; Van Glabekke, M.; Renard, 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 180 KB

Phase II clinical study of high-dose tor

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer

✍ H. Modig; S. Borgström; I. Nilsson; G. Westman 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Centchroman—a non-steroidal anti-cancer

Centchroman—a non-steroidal anti-cancer agent for advanced breast cancer: Phase-II study

✍ N. C. Misra; P. K. Nigam; Ruby Gupta; A. K. Agarwal; V. P. Kamboj 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 331 KB

Treatment with Centchroman (3,4-trans-2,2-dimethyl-3phenyl-4-p-(fl-pyrrolidinoethoxy) phenyl-7-methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. The overall response rate, including both male and female cases, was 40.5%. Among the female patients, the